Cerus (CERS) Registration filing summary

Company overview and business model

• Biomedical products focus on developing and commercializing INTERCEPT Blood System, designed to reduce blood-borne pathogens in donated blood components for transfusion.

• Platelet and plasma systems have FDA approvals and CE certification; cryoprecipitation system has FDA approval for producing IFC and pathogen-reduced plasma.

• Platelet and plasma systems are sold through direct sales and distributors; IFC and related kits are sold directly in the U.S. Red blood cell system remains in development.

Use of proceeds and capital allocation

• Net proceeds are intended for working capital and general corporate purposes, including R&D, SG&A and manufacturing, subject to offering-specific supplements.

• Pending use, net proceeds are intended for investment in short-term, investment-grade, interest-bearing securities.

Risk factors and disclosures

• U.S. commercialization of platelet, plasma and cryoprecipitation products is critical; limited adoption, market concentration or failure to transition to a kit model could materially harm results and growth.

• Clinical outcomes, regulatory approvals and certification are uncertain; the red blood cell system may never be approved, and manufacturing, sole-source supply and compliance risks may disrupt sales.

• Ongoing losses and inability to obtain capital or generate positive cash flow could force cuts to development, sales or commercialization activities.

• BARDA and DoD funding depends on continued support and milestone acceptance; reductions or delays could harm cash flow and suspend or end U.S. red blood cell development.

• Competition, intellectual property disputes, international operating complexity, trade tensions and geopolitical conflicts could adversely affect commercial opportunities and results.